Alnylam Q2 product revenue $214M (+33%); AMVUTTRA FDA approved; guidance reiterated

ALNYLAM PHARMACEUTICALS, INC.

2022-Q2 EPS reported -$4.29 revenue$438,077,000

Q2 net product revenues $214M: ONPATTRO $153M, GIVLAARI $45M, OXLUMO $15M, up 33% YoY.
FDA approved AMVUTTRA (vutrisiran) for hATTR polyneuropathy; 133 start forms in first weeks.
GAAP net loss $277M ($2.29/share) vs $190M loss year ago; non-GAAP loss $246M ($2.03).
Reiterated FY2022 guidance: combined product revenue $870-$930M, R&D+SG&A $1.62-$1.70B.
Expects APOLLO-B topline results within 3 weeks; cash $2.11B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.